TAKEDA PHARMACEUTICAL CO LTD (TAK) Form 6-K — Oct 29, 2026
Takeda reported H1 FY2026 (April-September 2026) revenue of JPY 2,407.0 billion, up 8.4% AER but down 1.0% at constant exchange rates, with net profit attributable to owners jumping 171.8% to JPY 305.6 billion, helped by lower impairment losses, deferred tax benefits and yen weakness. Core Operating Profit rose 11.2% AER to JPY 710.6 billion (only +0.7% CER), and ENTYVIO remained the growth engine at JPY 541.7 billion (+13.0% AER, +2.7% CER), while New Launches grew 17.3% CER. Takeda raised its FY2027 (March-end) forecast: revenue to JPY 4,700.0 billion, net profit to JPY 209.0 billion (+25.9% vs. original forecast) and EPS to JPY 131.28, largely on FX benefits and tax reassessment.
Key figures
- Eps
- 192.53
- Revenue
- 2407000000000
- Guidance
- FY ending March 2027: revenue JPY 4,700.0B, operating profit JPY 453.0B, net profit JPY 209.0B, EPS JPY 131.28, Core EPS JPY 482; CER guidance revised to low-single digit % Core Revenue decline, mid-single digit % Core OP decline, low-teens % Core EPS decline
- Net Income
- 305700000000
- Revenue Yoy
- 8.4% AER / -1.0% CER
- Total Assets
- 15271498000000
- Cash Position
- 418533000000
- Shares Outstanding
- 1602218559
- Operating profit
- JPY 406.7 billion (+60.4% AER)
- Operating cash flow
- JPY 431.9 billion (-27.2%)
- Core operating profit
- JPY 710.6 billion (+11.2% AER, +0.7% CER)
- Adjusted free cash flow
- JPY 325.7 billion (-38.0%)
- Annual dividend projection
- JPY 204
- Interim dividend per share
- JPY 102
- Adjusted net debt to ebitda
- 2.5x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.